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Probenecid inhibits the renal clearance of frusemide and its 
acyl glucuronide
TOM B. VREE1’2, MAGDALENA VAN DEN BIGGEL A AR-M ARTE A1 & CORRIEN P. W. G. M. VERWEY-VAN 
WISSEN'
'Department of Clinical Pharmacy, institute of Anaesthesiology, Academic Hospital Nijmegen Sint Radboud,
Geert Grooteplein Zuid 8, 6525 GA Nijmegen, Netherlands
The effect o f oral probenecid (1 g) on the pharmacokinetics o f frusemide (80 mg p.o.) 
and its acyl glucuronide was studied in nine healthy subjects. Probenecid significantly
increased the o f frusemide from 2.01 ± 0.68 to 3.40 ± 1.48 h (P  = 0.0015) and 
significantly decreased oral clearance from 164 ± 67.0 to 58.3 ± 28.1 ml min-1 (P = 
0.0001). No effect o f probenecid on the plasma protein binding o f frusemide was 
detected. Probenecid significantly increased the fmax o f the metabolite frusemide acyl 
glucuronide from 1.4 to 2.6 h, but had no effect on the iiag, Cmax, fi/2,z and plasma pro­
tein binding. The urinary recoveries o f unchanged frusemide (39.2 ± 10.2 vs 34.4 ± 
8.6%, P = 0 .28) and its acyl glucuronide (12.1 ± 2.7 vs 11.8 ± 3.7%, P  > 0.8) were
not altered by probenecid. However, probenecid decreased the renal clearance o f both
frusemide (128 ± 49 vs 44 .0  ± 18.6 ml min"1, P  = 0 .0002) and the acyl glucuronide 
(552 ± 298 158 ± 94.0 ml min-1, P  <  0.0001). The non-renal clearance o f  
frusemide (36.7 ± 21.0 vs 15.2 ± 13.4 ml min-1, P  = 0.0068) was also decreased. The
clinical relevance of the study relates to the possible conjugation o f frusemide in the 
kidney and the role o f the conjugate in the pharmacodynamic effect.
Keywords frusemide pharmacokinetics acyl glucuronide probenecid renal clearance
interaction
Introduction
Frusemide is metabolised to an acyl glucuronide 
(1-0-glucuronide) in man [1-3]. Acyl glucuronides 
are unstable at slightly alkaline pH, undergoing
The presence of isoglucuronides (2-, 3-, and 4-0-  
glucuronide) in urine is expected because of isomeri­
zation in blood at pH 7.4 [5-7], To prevent acyl 
glucuronide degradation in urine in vivo, the urine 
must be kept acidified to pH values of about 5.0
[4, 6-8].
Pharmacodynamic and pharmacokinetic modelling 
have correlated frusemide kinetics with the kinetics 
of chloride, sodium and the urine production but have 
neglected the possible effect of the acyl glucuronide
[5, 9, 10].
Several studies have reported that probenecid 
increases the plasma concentration of frusemide, sug­
gesting inhibiton of its tubular secretion [11-14]. In 
addition, if glucuronidation of frusemide occurs in 
the kidney during cellular transport [15, 16], as pre­
viously suggested for indomethacin [17, 18], nalidixic 
acid [19] and probenecid [20], probenecid might 
inhibit this process.
The aims of this investigation were to study in 
healthy volunteers a) the effect of probenecid on the 
glucuronidation of frusemide, and b) the effect of 
probenecid on the renal excretion of parent drug and 
its acyl glucuronide. The clinical relevance of the 
study relates to the possible conjugation of frusemide 
in the kidney and the role of the conjugate in the 
pharmacodynamic effect.
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Methods frusemide were calculated by standard methods [22]. 
The intrinsic mean residence time (MRTj) was
Nine subjects (six males, three females 35 ± 6 (s.d.) 
years, 78 ± 8 (s.d.) kg) participated in the study. In a 
cross-over design they took 80 mg frusemide orally 
(Lasix®) after an overnight fast and again 2 weeks 
later after an overnight fast and 1 h after the oral 
administration of 1 g probenecid (Benemid®, MSD, 
Haarlem Netherlands). The study was approved by 
the hospital ethics committee and the subjects gave 
their informed consent.
Fingertip blood samples (2 ml), obtained with 
Monolet® lancets (Monoject, St Louis, USA), were 
collected in heparinised Eppendorf® vials (2 ml) at 
various times up to 12 h. After centrifuging, 
was stored at -20° C pending analysis.
Urine was collected up to 12 h. Urinary pH was 
kept acid (pH 5.0-5.5) by the oral administration 
of 1 g ammonium chloride four times
defined as MRTi = MRTmctaboiite-MRTparent. Total renal 
clearances (C L r) were calculated by dividing the
total urinary recovery by the corresponding
AUC(0, 12h). Non-renal clearance (CLnr) was de­
fined as C L nr = CLo-C L r.
Results
Plasma concentrations and urinary excretion rates of 
frusemide and its acyl glucuronide in a representative
treatment aresubject with and without 
shown in Figure 1. Table 1 summarises mean pharma-
The i1/2,z 
curonide were 2.01
frusemide and acyl glu
± 0.68 h and 2.69 ± 1.48 h
(Ammonchlor®, Siidmedica, Munich, Germany). Four 
urine samples of 5 ml from each void were stored 
immediately at -20° C pending analysis.
Each urine void (of ± 300 ml) was followed by 
ingestion of 100 ml water.
Drug analysis
Frusemide and its acyl glucuronide were assayed by 
h.p.l.c. as described by Vree et al. [21].
of quantitation of frusemide and its
respectively (P = 0.21).
Probenecid increased the fmax values of frusemide 
and its acyl glucuronide and the ft/2,z of frusemide; it 
did not change the ii/2,z of the glucuronide 
cantly, nor the MRT values of both compounds. The 
oral clearance of frusemide, the renal clearance and 
the non-renal clearance of frusemide were decreased 
by probenecid to approximately 35% of their baseline 
value, but their urinary recoveries were unaltered. As 
a result of decreased oral and renal clearance the 
AUC of frusemide as well as its glucuronide 
increased three-fold. Probenecid did not influence the 
plasma binding of either frusemide or its glucuronide.
The
acyl glucuronide in plasma were 0.007 |lg ml"1, and 
0.01 jug ml-1 respectively. The limits of quantitation 
in urine were 0.10 us ml-1 and 0.15 U2 ml-1
Discussion
M'S
spectively. The intra- and 
the assays were <5% [21].
re-
coefficients of Probenecid decreased the oral clearance and renal
clearance of frusemide, with previous
Plasma samples (100 111) were deproteinized with reports [11, 12, 14]. Also the calculated non-
100 |il acetonitrile, centrifuged at 3000 g, 20 u.1 of clearance of frusemide was decreased, which may
the supernatant was injected immediately onto the 
column. Frusemide acyl glucuronide is only stable at 
pH 7.4 for 30 min.
Urine samples were diluted 1:1 with water, and 
20 JlXI was injected into the column.
Plasma binding
The plasma binding of frusemide and and its acyl 
glucuronide was measured in ex vivo samples using 
the Amicon Micropartition system MPS-1 (Grace BV, 
Amico Division, Capelle aan de IJssel, Netherlands). 
The average binding (± s.d.) was calculated from two 
plasma samples from each volunteer obtained 1-2 h 
after drug administration. No non-specific drug bind­
ing to the filters was observed.
indicate that active secretion into bile, or the rate of 
hepatic glucuronidation is decreased. All three clear­
ance parameters were reduced to approximately 35% 
of their baseline value.
Probenecid had no effect on the flag, Cmax, and tin>/. 
of frusemide acyl glucuronide but decreased the renal 
clearance of the metabolite to approximately 30% of 
its baseline value. Therefore tubular secretion of the 
metabolite is partly inhibited by probenecid, leaving
arance which is still higher than the 
glomerular filtration rate. The extremely high appar-
a
ent renal clearance of frusemide glucuronide
Data analysis
Curve fitting was carried out using the MediWare
which is four times higher than that of the parent 
drug, suggests that the kidney contributes to the over­
all glucuronidation of frusemide. The effect of pro­
benecid on the renal clearance of both parent drug 
and acyl glucuronide is of the same 
reduces the renal clearance to approximately 35% of 
its baseline value.
Renal excretion is the main route of elimination
computer program [22]. Values of Cmax, Wx and tiag of frusemide (40%), with metabolic conjugation
were noted directly from the data. AUC(0, I2h) values 
were calculated using the linear trapezoidal rule. Oral 
clearance (CL0) and mean residence time (MRT) of
accounting for 12%. Thus 50% of the oral dose is 
unaccounted for.
Impaired kidney function will reduce the renal se-
© 1995 Blackwell Science Ltd, British Journal o f Clinical Pharmacology, 39, 692-695
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Figure 1 Plasma concentrations and urinary excretion rates of frusemide (F), frusemide acyl glucuronide (Fgluc) in a 
representative subject after an oral dose of 80 mg frusemide without (a) and with (b) probenecid (1 g).
Table 1 Pharmacokinetic parameters of frusemide (80 mg) with and without probenecid (lg)
Parameter
Mean + s.d. 
without with probenecid
95% 
confidence 
interval 
of difference P
Frusemide
flag (h) 0.26 ± 0.21 0.51 ± 0.58 -0.76-0.27 0.07
tmax (h) 0.79 (0.6-1.37) 1.93 (0.16-2.46) -1.30- -0.07 0.0273
Cmnx (M'S *) 1.79 ±0.65 2.77 ± 1.71 -2.30-0.36 0.0284
t i/,,Z (h) 2.01 ± 0.68 3.40 ± 1.48 -2.70- -0.14 0.0015
MRT (h) 2.67 ± 0.46 4.41 ± 1.14 -2.64- -0.84 0.0258
AUC(0,12h) (mg H  h) 4.46 ±1.13 11.95 ±4.58 -10.4- -4.34 <0.0001
CLo (ml min“1) 164.0 ±67.0 58.3 ± 28.1 63.9-149.0 0.0001
CLr (ml min-1) 128.0 ±49.1 44.0 ± 18.6 53.6-83.7 0.0002
CLnr (ml min"1) 36.7 ±21.0 15.2 ± 13.4 8.66-34.4 0.0068
Urinary recovery (% |j.mol dose) 39.3 ± 10.2 34.4 ± 8.6 0.39-9.48 0.28
Plasma binding (%) 97.8 ± 1.9 98.8 ± 0.7 -3.30-8.25 0.30
Frusemide acylglucuronide
/lag (h) 0.30 ±0.17 0.53 ± 0.60 -0.77-0.31 0.10
fnwx (h) 1.43 (0.78-2.59) 2.59 (0.50-2.59) -2.42- -0.06 0.0391
Cmax (M-g ml’1) 0.09 ± 0.06 0.18 ±0.12 -0.15-0.03 0.07
t to,/. (h) 2.69 ± 1.48 2.82 ± 0.91 -1.25-1.07 0.77
MRT (h) 3.82 ± 1.32 5.75 ± 1.98 -3.08- -0.79 0.0196
MRTi (h) 1.54 ± 1.31 2.17 ± 0.96 -1.77-0.71 0.52
AUC(0,12h) (mg l“1 h) 0.43 ± 0.35 1.33 ± 0.85 -1.51--0.29 0.0097
CLr (ml min-1) 552.0 ± 298 158.0± 94.0 197.0-591 <0.0001
Urinary recovery (% jxmol dose) 12.1 ± 2.7 11.8 ± 3.7 -18.6-2.51 >0.8
Plasma binding (%) 95.5 ± 1.8 94.2 ± 5.7 -10.2-40.1 0.58
Values are expressed as mean ± s.d except im»x (median and range (n = 9).
cretion of both parent drug and conjugate. Reduction 
of kidney function by probenecid did not affect the 
percentage of the dose recovered as frusemide glu­
curonide; however, it slowed the elimination pro­
cesses. Impaired kidney function (for example in 
older patients) will therefore not alter the overall
yield (%) of glucuronidation. It is not yet certain 
whether frusemide alone, or its acyl glucuronide or 
both are active diuretics. To solve this question both 
parent drug and conjugate will need to be included in 
pharmacodynamic-pharmacokinetic modelling of 
frusemide.
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